Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04307381 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04307381 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT04307381, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).
Interventions
- DRUG Donidalorsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-03-31 |
| Est. Completion | 2025-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04307381
The ClinicalTrials.gov registry entry for NCT04307381 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Donidalorsen is the first listed.
NCT04307381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04307381 about?
NCT04307381 is a clinical study titled "An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema". The purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).
What is the current status of trial NCT04307381?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-03-31. Estimated completion is 2025-01-24.
What interventions are being tested in trial NCT04307381?
The interventions under investigation include: Donidalorsen (DRUG).
Who is sponsoring clinical trial NCT04307381?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.